Search results
Showing 61 to 75 of 309 results for breast cancer
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1089
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
In development Reference number: GID-TA11439 Expected publication date: 10 September 2026
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
In development Reference number: GID-TA11402 Expected publication date: TBC
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
View recommendations for MTG72Show all sections